BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol 2015; 21(42): 12101-12113 [PMID: 26576095 DOI: 10.3748/wjg.v21.i42.12101]
URL: https://www.wjgnet.com/1948-5182/full/v21/i42/12101.htm
Number Citing Articles
1
Anand Bhushan, Sumona Ghosh, Samsiddhi Bhattacharjee, Sreedhar Chinnaswamy. Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus InfectionJournal of Interferon & Cytokine Research 2017; 37(8): 369 doi: 10.1089/jir.2017.0002
2
Stuart C. Gordon, Sheri Trudeau, Jia Li, Yueren Zhou, Loralee B. Rupp, Scott D. Holmberg, Anne C. Moorman, Philip R. Spradling, Eyasu H. Teshale, Joseph A. Boscarino, Yihe G. Daida, Mark A. Schmidt, Mei Lu. Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United StatesJournal of Clinical Gastroenterology 2019; 53(1): 40 doi: 10.1097/MCG.0000000000000872
3
Figen Sarıgul, Murat Sayan, Ulku User, Nefise Oztoprak. Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict RulesHepatitis Monthly 2019; (In Press) doi: 10.5812/hepatmon.62390
4
E. Gane, R. Nahass, V. Luketic, E. Asante‐Appiah, P. Hwang, M. Robertson, J. Wahl, E. Barr, B. Haber. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment‐naïve, noncirrhotic HCV genotype 3‐infected patientsJournal of Viral Hepatitis 2017; 24(10): 895 doi: 10.1111/jvh.12719
5
Zayar Phyo, Ko Ko, Serge Ouoba, Aya Sugiyama, Ulugbek Khudayberdievich Mirzaev, Golda Ataa Akuffo, Chanroth Chhoung, Tomoyuki Akita, Junko Tanaka, Yury E. Khudyakov. Intermediate hepatitis C virus (HCV) endemicity and its genotype distribution in Myanmar: A systematic review and meta-analysisPLOS ONE 2024; 19(9): e0307872 doi: 10.1371/journal.pone.0307872
6
Maia Butsashvili, Lia Gvinjilia, George Kamkamidze, David Metreveli, Shorena Dvali, Tamar Rukhadze, Amiran Gamkrelidze, Muazzam Nasrullah, Shaun Shadaker, Juliette Morgan, Francisco Averhoff. High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in GeorgiaBMC Research Notes 2020; 13(1) doi: 10.1186/s13104-020-05173-4
7
Xi Ran, HuaiYi Xie, Wei Li. Sustained Virologic Response Rates of Sofosbuvir and Velpatasvir in Patients with Hepatitis C Genotype 3: A Meta-AnalysisHepatitis Monthly 2020; 20(1) doi: 10.5812/hepatmon.98798
8
Mariana Sandoval Lourenço, Patricia Momoyo Y Zitelli, Marlone Cunha-Silva, Arthur Ivan N Oliveira, Cláudia P Oliveira, Tiago Sevá-Pereira, Flair José Carrilho, Mario G Pessoa, Daniel F Mazo. Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in BrazilWorld Journal of Hepatology 2022; 14(1): 195-208 doi: 10.4254/wjh.v14.i1.195
9
Qunying Han, Xiude Fan, Xiaoyun Wang, Ye Wang, Huan Deng, Xiaoge Zhang, Kun Zhang, Na Li, Zhengwen Liu. High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world settingVirology Journal 2019; 16(1) doi: 10.1186/s12985-019-1184-y
10
Hilla Knobler, Stephen Malnick. Hepatitis C and insulin action: An intimate relationshipWorld Journal of Hepatology 2016; 8(2): 131-138 doi: 10.4254/wjh.v8.i2.131
11
Jia‐Horng Kao, Sang Hoon Ahn, Rong‐Nan Chien, Mong Cho, Wan‐Long Chuang, Sook‐Hyang Jeong, Chen‐Hua Liu, Seung‐Woon Paik. Urgency to treat patients with chronic hepatitis C in AsiaJournal of Gastroenterology and Hepatology 2017; 32(5): 966 doi: 10.1111/jgh.13709
12
Jyoti Gupta, Minnah Irfan, Niranjan Ramgir, K. P. Muthe, A. K. Debnath, Shabnam Ansari, Jaya Gandhi, C. T. Ranjith-Kumar, Milan Surjit. Antiviral Activity of Zinc Oxide Nanoparticles and Tetrapods Against the Hepatitis E and Hepatitis C VirusesFrontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.881595
13
Mai H. A. Mousa, Nermin S. Ahmed, Kai Schwedtmann, Efseveia Frakolaki, Niki Vassilaki, Grigoris Zoidis, Jan J. Weigand, Ashraf H. Abadi. Design and Synthesis of Novel Symmetric Fluorene-2,7-Diamine Derivatives as Potent Hepatitis C Virus InhibitorsPharmaceuticals 2021; 14(4): 292 doi: 10.3390/ph14040292
14
Abhilasha Madhvi, Smita Hingane, Rajpal Srivastav, Nishant Joshi, Chandru Subramani, Rajagopalan Muthumohan, Renu Khasa, Shweta Varshney, Manjula Kalia, Sudhanshu Vrati, Milan Surjit, C. T. Ranjith-Kumar. A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compoundScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-04449-3
15
Yilihamu Abulitifu, Jiangshan Lian, Munire Adilijiang, Lan Liu, Fengcong Zhao, Wen Qian, Yongping Zhang. Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, ChinaInfection and Drug Resistance 2022; : 6463 doi: 10.2147/IDR.S385071
16
Steven W. Johnson, Dorothea K. Thompson, Brianne Raccor. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic InterventionsCurrent Infectious Disease Reports 2017; 19(6) doi: 10.1007/s11908-017-0578-5
17
Nikolaos Lougiakis, Efseveia Frakolaki, Panagiota Karmou, Nicole Pouli, Panagiotis Marakos, Vanesa Madan, Ralf Bartenschlager, Niki Vassilaki. Novel nucleoside analogues targeting HCV replication through an NS5A‐dependent inhibition mechanismChemical Biology & Drug Design 2017; 90(3): 352 doi: 10.1111/cbdd.12966
18
Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in IndiaHepatology International 2019; 13(2): 173 doi: 10.1007/s12072-019-09927-6
19
Vasiliki Pardali, Erofili Giannakopoulou, George Mpekoulis, Vassilina Tsopela, Georgios Panos, Martin C. Taylor, John M. Kelly, Niki Vassilaki, Grigoris Zoidis. Novel Lipophilic Hydroxamates Based on Spirocarbocyclic Hydantoin Scaffolds with Potent Antiviral and Trypanocidal ActivityPharmaceuticals 2023; 16(7): 1046 doi: 10.3390/ph16071046